CureVac starts Phase IIb trial of CV9104

A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Is possible new prostate cancer vaccine really “promising”?

A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …

University of Iowa starts Phase II trials with Ad/PSA vaccine

A research team at the University of Iowa is seeking patients to enroll in Phase II clinical trials of a new form of vaccine immunotherapeutic to treat men with recurrent prostate cancer. … READ MORE …

Are “universal” cancer vaccines feasible and clinically effective?

The idea that we might be able to use a single therapeutic “vaccine” to treat patients with  many different types of cancer is not new … and has yet to be substantiated in any large clinical trial. However, … READ MORE …

ProstAtak, Theragene, and the evolution of “vaccine-like” therapies for prostate cancer

In May this year we initially commented on a media announcement about a new form of vaccine-like therapy that was entering Phase III clinical trials for the first-line treatment of intermediate- and high-risk prostate cancer. … READ MORE …

New vaccine supposedly “cures prostate cancer in mice”

Now curing prostate cancer in mice absolutely does not necessarily imply that the same vaccine can be used to “cure prostate cancer in man,” … but the technical capability is certainly a step in the right direction (if it really is true). … READ MORE …

New Phase III trial of “gene suicide therapy” in localized prostate cancer

A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer. … READ MORE …

On the feasibility of a “universal” cancer vaccine (but first in prostate cancer)

As some readers may be aware, one of the great biologic discoveries of the late 20th Century was the association between the length of the telomere (a piece of repeating DNA at the tips of each chromosome) and the ability of an individual cell to divide and replicate. … READ MORE …

AE37 shows initial activity in Phase I prostate cancer trial

Research into new “vaccine” immunotherapies for prostate cancer continues to be a hot topic following the approval of Dendreon’s Provenge just 3 weeks ago. … READ MORE …

New data on prostate cancer vaccine BPX-101

Straight from a “late-breaking poster” at the annual meeting of the Association for the Advancement of Cancer Research going on in Washington, DC, comes data about BPX-101 — another dendritic cell-based immunotherapeutic “vaccine” for the possible treatment of late-stage prostate cancer. … READ MORE …

Another new vaccine starts Phase I clinical trials

We have heard that another investigational vaccine therapy has started Phase I clinical trials that will include patients with advanced prostate cancer who “have failed at least 1 course of an accepted hormonal therapy.” … READ MORE …

A Phase III clinical trial of PROSTVAC-VF may be in the offing

According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC). … READ MORE …

New prostate cancer “vaccine” effective in Phase I trial

While we are all waiting for the approval of Provenge, it is worth noting that a research group at the University of Iowa has developed a very different type of prostate cancer treatment based on older technology. … READ MORE …

Social behavior and prostate cancer prevention

In another front-page article this morning, the New York Times discusses the failure of potential patients and the medical community to take seriously the opportunities actually proven to prevent certain types of cancer. … READ MORE …

Prostate cancer news update: Friday, August 21, 2009

In today’s reports we note items related to:

  • Whether add-back estrogen improves cognitive function in men on ADT
  • Exercise and its impact on the side effects of ADT
  • A new technique for delivering prostate cancer “vaccines”
  • The potential of VEGF inhibitors in prostate cancer treatment … READ MORE …
Follow

Get every new post delivered to your Inbox.

Join 825 other followers